Analysis: Iovance Biotherapeutics Inc (IOVA) is showing strong momentum in premarket trading and has received positive sentiment scores. The recent FDA approval of Amtagvi, a T cell immunotherapy for advanced melanoma, is a significant milestone and a potential catalyst for future growth.3 Investors should consider IOVA's strong overall scores, positive sentiment, and the promising outlook for Amtagvi in their investment decisions.